<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00363350</url>
  </required_header>
  <id_info>
    <org_study_id>METc2005.229</org_study_id>
    <nct_id>NCT00363350</nct_id>
  </id_info>
  <brief_title>Rituximab Treatment in Sjogren's Syndrome</brief_title>
  <official_title>Rituximab for the Treatment of Primary Sjögren's Syndrome: a Double Blinded Randomized Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <brief_summary>
    <textblock>
      This study is an evaluation of the effect of rituximab compared to placebo in combination&#xD;
      with steroids on salivary flow and serological and clinical parameters in patients with&#xD;
      primary SS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:&#xD;
&#xD;
      phase II trial&#xD;
&#xD;
      Study objective:&#xD;
&#xD;
      evaluation of the effect of rituximab compared to placebo in combination with steroids on&#xD;
      salivary flow and serological and clinical parameters in patients with primary SS&#xD;
&#xD;
      Number of participating centres:&#xD;
&#xD;
      1&#xD;
&#xD;
      Duration:&#xD;
&#xD;
      follow-up 48 weeks&#xD;
&#xD;
      Study medication:&#xD;
&#xD;
      2 infusions on day 1 and day 15 rituximab infusions (1000 mg) or placebo infusions&#xD;
      intravenous infusion of 100 mg of methylprednisolone before infusion of rituximab (or the&#xD;
      placebo for rituximab), together with 60 mg per day of oral prednisone on days 2, 3, 16 and&#xD;
      17, 30 mg per day on days 4, 5, 18 and 19 and 15 mg per day on days 6 and 20&#xD;
&#xD;
      Primary objective/endpoint:&#xD;
&#xD;
      stimulated salivary gland function (stimulated submandibular/sublingual and parotid saliva)&#xD;
&#xD;
      Secondary objectives/endpoint:&#xD;
&#xD;
      Functional parameters Laboratory parameters Subjective parameters Histological/Molecular&#xD;
      parameters&#xD;
&#xD;
      Number of subjects:&#xD;
&#xD;
      30 patients with primary SS (20 patients rituximab treatment, 10 patients placebo)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>stimulated whole salivary flow rate</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional parameters</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameters</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective parameters</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological/Molecular parameters</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Sjogren's Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab (anti-CD20)</intervention_name>
    <description>2 infusions of 1000 mg</description>
    <other_name>Mabthera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stimulated whole saliva secretion ≥ 0,15 ml/min&#xD;
&#xD;
          -  Male or female &gt; 18 years&#xD;
&#xD;
          -  Primary SS according to the revised European - U.S. criteria(22)&#xD;
&#xD;
          -  Positive autoantibodies (IgM-Rf &gt; 10 and SS-A and/or SS-B)&#xD;
&#xD;
          -  Parotid gland biopsy (paraffine material and fresh frozen tissue) with characteristic&#xD;
             features of SS performed at time of inclusion (no longer than 12 months ago)&#xD;
&#xD;
          -  Use of reliable method of contraception during the study&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The presence of any other connective tissue disease&#xD;
&#xD;
          -  Preceding treatment with anti-TNF or other monoclonal antibodies&#xD;
&#xD;
          -  Use of prednisone, hydroxychloroquine less than 1 month ago&#xD;
&#xD;
          -  Use of MTX, cyclophosphamide, cyclosporin, azathioprine and other DMARDS less than 0,5&#xD;
             year ago&#xD;
&#xD;
          -  Serum creatine &gt; 2.8 mg/dl (250 micromol/l)&#xD;
&#xD;
          -  ASAT or ALAT outside 1.5 x upper normal range of the laboratory&#xD;
&#xD;
          -  Hb &lt; 9 g/dl (5.6 mmol/l) for males and 8.5 g/dl (5.3 mmol/l) for females&#xD;
&#xD;
          -  Neutrophil granulocytes less than 0.5 x 109/l&#xD;
&#xD;
          -  Platelet count less then 50 x 109/l&#xD;
&#xD;
          -  Positive pregnancy test or breast-feeding&#xD;
&#xD;
          -  History of alcohol or drug abuse&#xD;
&#xD;
          -  Serious infections&#xD;
&#xD;
          -  Underlying cardiac, pulmonary, metabolic, renal or gastrointestinal conditions,&#xD;
             chronic or latent infectious diseases or immune deficiency which places the patient at&#xD;
             an unacceptable risk for participation in the study&#xD;
&#xD;
          -  History of any malignancy with the exception of completely resected basal cell&#xD;
             carcinoma of the skin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiska Meijer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Centre Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG, Bootsma H. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum. 2005 Sep;52(9):2740-50.</citation>
    <PMID>16142737</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>August 10, 2006</study_first_submitted>
  <study_first_submitted_qc>August 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <last_update_submitted>February 23, 2009</last_update_submitted>
  <last_update_submitted_qc>February 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>H Bootsma</name_title>
    <organization>University Medical Centre Groningen</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

